Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: A prospective, randomized, placebo-controlled, double-blind study

British Journal of Anaesthesia

Volumn 96, Issue 3, 2006, Pages 377-380

  Agarwal, A ^a   Dhiraaj, S ^a   Singhal, V ^a   Kapoor, R ^a   Tandon, M ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Complications, Bladder discomfort; Drugs, Oxybutynin; Drugs, tolterodine; Surgery, urological

Indexed keywords

CYSTRAN; FENTANYL; ONDANSETRON; OXYBUTYNIN; PLACEBO; PROPOFOL; TOLTERODINE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BALLOON CATHETER; BLADDER CATHETERIZATION; BLADDER DISCOMFORT; BLURRED VISION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; NEPHROLITHOTOMY; POSTANESTHESIA CARE; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URETER STONE; XEROSTOMIA;

EID: 33244488049     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/ael003     Document Type: Article

References (14)

1. Andersson KE. The pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45: 253-308
2. Andersson KE. Advances in the pharmacological control of the bladder. Exp Physiol 1999; 84: 195-213
3. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended release oxybutynin chloride and tolterodine in the treatment of overactive bladder: Results of the OBJECT study. Mayo Clin Proc 2001; 76: 358-63
4. Agarwal A, Raza M, Singhal V, et al. The efficacy of tolterodine for prevention of catheter related bladder discomfort: A prospective, randomized, placebo-controlled, double blind study. Anesth Analg 2005; 101: 1065-7
5. de Groat WC. Anatomy and physiology of the lower urinary tract. Urol Clin North Am 1993; 20: 383-401
6. Diokno AC, Lapides J. Oxybutynin: A new drug with analgesic and anticholinergic properties. J Urol 1972; 108: 307-9
7. Yanker YE, Goa KL, Fitton A. Oxybutynin: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 243-62
8. Clmett D, Jarvis B. Tolterodine: A review of its use in the treatment of overactive bladder. Drugs Aging 2001; 18: 277-304
9. Larsson G, Hallen B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: Analysis of the pooled phase II efficacy and safety data. Urology 1999; 53: 990-8
10. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine a new antimuscarinic agent as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 801-10
11. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with obstructive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10: 283-9
12. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997; 50: 90-6
13. Robinson J. Fundamental principles of indwelling urinary catheter selection. Br J Community Nurs 2004; 9: 281-4
14. Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine - a new bladder selective antimuscarinic agent Eur J Pharmacol 1997; 327: 195-207